Alessandro Armuzzi
IBD Center at IRCCS Humatitas Research Hospital - Department of Biomedical Sciences · Istituto Clinico Humanitas · Policlinico Universitario Agostino Gemelli Università Cattolica del Sacro Cuore
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Alessandro Armuzzi as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 22:20 UTC. Open this list on ClinicalTrials.gov
- N/ANCT07433946 · Partial Enteral Nutrition to Prevent Weight Loss and Sarcopenia in IBD Patients at Nutritional Risk - SIMBALionhealth Srl Società Benefit · recruiting · Ulcerative Colitis (Disorder), Crohn Disease, Malnutrition or Risk of Malnutrition · principal investigator
- N/ANCT06569888 · Utility of Low Intensity Pulsed Ultrasound Stimulation (LIPUS) to Modulate the Release of Mediators Capable of Reflecting the Inflammatory State in the Affected Colonic Tract of Ulcerative Colitis PatientsIstituto Clinico Humanitas · unknown · Ulcerative Colitis · principal investigator
- N/ANCT03415711 · PRObiotic VSL#3® for Maintenance of Clinical and Endoscopic REMission in Ulcerative ColitisVSL Pharmaceuticals · terminated · Ulcerative Colitis · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 22:20 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 22:20 UTC. The ranking covers the 200 most relevant of 50 PubMed records, and a shared surname and initials can bring in a namesake. All 50 on PubMed
- Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.Lancet · 2017777 citationsRCR 35.3
- Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease.N Engl J Med · 2015334 citationsRCR 10.2
- Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis.Aliment Pharmacol Ther · 2006328 citationsRCR 8.9
- Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease.Gastroenterology · 2020279 citationsRCR 13.8
- Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study.Am J Gastroenterol · 2002227 citationsRCR 6.9
- Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease.Gastroenterology · 2020224 citationsRCR 13.2
- The effect of oral administration of Lactobacillus GG on antibiotic-associated gastrointestinal side-effects during Helicobacter pylori eradication therapy.Aliment Pharmacol Ther · 2001196 citationsRCR 6.5
- A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates.Aliment Pharmacol Ther · 2000166 citationsRCR 5.0
- Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection.Aliment Pharmacol Ther · 2000143 citationsRCR 5.3
- 137 citationsRCR 23.6